You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
|
|---|---|
| Published in |
Arthritis Research & Therapy, February 2016
|
| DOI | 10.1186/s13075-016-0937-x |
| Pubmed ID | |
| Authors |
Mirko Manetti, Serena Guiducci, Marco Matucci-Cerinic |
| Abstract |
In systemic sclerosis (SSc), peripheral vasculopathy is characterized by a progressive and irreversible loss of capillaries following endothelial cell injury, due to defects in both vascular repair and expected increase in new vessel growth (angiogenesis). The discovery of key molecular targets may help to develop the most effective therapeutic strategy for the SSc-related vasculopathy. A pathway worth targeting in SSc may include vascular endothelial growth factor, 165b isoform, an endogenous angiogenesis inhibitor abnormally expressed and released by different cell types, including activated endothelial cells and platelets. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Singapore | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 7% |
| Unknown | 13 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 21% |
| Student > Master | 3 | 21% |
| Lecturer | 1 | 7% |
| Student > Ph. D. Student | 1 | 7% |
| Student > Postgraduate | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 5 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 3 | 21% |
| Medicine and Dentistry | 2 | 14% |
| Nursing and Health Professions | 1 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Agricultural and Biological Sciences | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 5 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2016.
All research outputs
#15,740,207
of 25,374,917 outputs
Outputs from Arthritis Research & Therapy
#2,289
of 3,381 outputs
Outputs of similar age
#216,041
of 406,035 outputs
Outputs of similar age from Arthritis Research & Therapy
#57
of 69 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,035 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.